CIDEB and CGI-58 Regulate Liver Lipid Droplet Size with Cholesterol Content, Linking to Inflammation and Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis

被引：0
|
作者：
Sakuma, Ikki
Gaspar, Rafael C.
Nasiri, Ali
Kahn, Mario
Zheng, Jie
Guerra, Mateus
Yimlamai, Dean
Murray, Sue
Perelis, Mark
Barnes, William
Vatner, Daniel F.
Petersen, Kitt
Samuel, Varman
Shulman, Gerald I.
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1571-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1571-P
引用
收藏
页数：2
相关论文
共 44 条
  • [1] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
    Loomba, Rohit
    Hartman, Mark L.
    Lawitz, Eric J.
    Vuppalanchi, Raj
    Boursier, Jerome
    Bugianesi, Elisabetta
    Yoneda, Masato
    Behling, Cynthia
    Cummings, Oscar W.
    Tang, Yuanyuan
    Brouwers, Bram
    Robins, Deborah A.
    Nikooie, Amir
    Bunck, Mathijs C.
    Haupt, Axel
    Sanyal, Arun J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 299 - 310
  • [2] Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis
    Steffani, Marcella
    Geng, Yana
    Pajvani, Utpal B.
    Schwabe, Robert F.
    JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (07):
  • [3] Coenzyme A Synthase Knockdown Alleviates Metabolic Dysfunction-Associated Steatohepatitis via Decreasing Cholesterol in Liver Lipid Droplets
    Sakuma, Ikki
    Gaspar, Rafael C.
    Nasiri, Ali
    Kahn, Mario
    Guerra, Mateus
    Yimlamai, Dean
    Murray, Sue
    Perelis, Mark
    Barnes, William
    Vatner, Daniel F.
    Petersen, Kitt
    Samuel, Varman
    Shulman, Gerald I.
    DIABETES, 2024, 73
  • [4] Hepatocyte programmed cell death: the trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis
    Cheng, Zilu
    Chu, Huikuan
    Seki, Ekihiro
    Lin, Rong
    Yang, Ling
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [5] Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis
    Fan, Xingyu
    Wang, Yueyue
    Wang, Yue
    Duan, Hao
    Du, Yijun
    Pan, Tianrong
    Zhong, Xing
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [6] Sphingosine-1-phosphate promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis
    Osawa, Yosuke
    Kawai, Hironari
    Nakashima, Keigo
    Nakaseko, Yuichi
    Suto, Daisuke
    Yanagida, Keisuke
    Hashidate-Yoshida, Tomomi
    Mori, Taizo
    Yoshio, Sachiyo
    Ohtake, Takaaki
    Shindou, Hideo
    Kanto, Tatsuya
    PLOS ONE, 2024, 19 (05):
  • [7] Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis
    Saito, Takashi
    Tsuchishima, Mutsumi
    Tsutsumi, Mikihiro
    George, Joseph
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (12)
  • [8] Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
    Vidal-Cevallos, Paulina
    Chavez-Tapia, Norberto
    MED, 2024, 5 (05): : 375 - 376
  • [9] Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis
    Tincopa, Monica A.
    Loomba, Rohit
    SEMINARS IN LIVER DISEASE, 2024, 44 (03) : 287 - 299
  • [10] Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma
    El-Kassas, Mohamed
    Othman, Heba A.
    Elbadry, Mohamed
    Alswat, Khalid
    Yilmaz, Yusuf
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2025, 15 (01)
12345